Theravance Biopharma

YUPELRI And Ampreloxetine Will Capitalize On Secular Trends

AnalystHighTarget

Not Invested

Consensus Narrative from 5 Analysts

Published

04 Sep 25

AnalystHighTarget's Fair Value

US$26.00

46.5% undervalued

04 Sep

US$13.92

74.0%

0.3%

74.0%

0.3%

Edit anytime before Sep 4 9:26 PM. Then post Updates to your followers.

Author's Valuation

US$26.0

46.5% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$26.0

46.5% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

18.39%

Pharma revenue growth rate

0.60%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$57.45m

Earnings '28

29.75x

PE Ratio '28

US$1.71b

Market Cap '28

US$1.71b

Market Cap '28

54.10m

No. shares '28

US$31.59

Share Price '28

US$31.59 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$25.95

Fair Value '25